{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-106975","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2024-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.058102+00:00","generated_at":"2026-06-03T12:25:02.490219+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MAIA Biotechnology raises $1.0M via private placement of 494,096 shares at $2.034/sh and warrants","bullets":["Gross proceeds $1.0M from sale of 494,096 shares at $2.034/sh and warrants to purchase same number at $2.26.","Director Stan Smith purchased 147,492 shares/warrants for ~$300k; Louie Ngar Yee purchased 19,665 for ~$40k.","Warrants exercisable at $2.26, commencing 6 months from issuance, term 5 years.","Net proceeds to fund first third of THIO-101 Part C trial for non-small cell lung cancer.","Closing expected on or about April 25, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-106975","json":"https://secwatch.observer/filing/0001193125-24-106975.json","markdown":"https://secwatch.observer/filing/0001193125-24-106975.md","text":"https://secwatch.observer/filing/0001193125-24-106975.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000119312524106975/0001193125-24-106975-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000119312524106975/d815817d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T12:25:02.490219+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f2d75c5f3bdfa14038d80f77993c0813775fafc5","claim":"MAIA Biotechnology, Inc. entered into \"Purchase Agreement\" with certain accredited investors valued at aggregate purchase price of approximately $664,994 (effective 2024-04-22).","evidence_excerpt":"On April 22, 2024, MAIA Biotechnology, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Investors ”) for the issuance and sale in a private placement (the “ Private Placement ”) of: (i) 326,939 shares (the “ Investor Shares ”) of the Company’s common stock, par value $0.0001 per share (“ Common Stock ”), and (ii) warrants (the “ Investor Warrants ”) to purchase up to 326,939 shares of Common Stock, at a price per share of $2.034, for an aggregate purchase price of approximately $664,994.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1878313/000119312524106975/0001193125-24-106975-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain accredited investors"},{"label":"Value","value":"aggregate purchase price of approximately $664,994"},{"label":"Effective","value":"2024-04-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}